Viral Load May Be Best Biomarker For IBTs, Antiviral Advisory Cmte Suggests
Executive Summary
Viral load is probably the best available biomarker for the clinical efficacy of immune-based therapies, provided changes in plasma HIV RNA levels can be linked with a therapy's immunological benefit, FDA's Antiviral Drugs Advisory Committee suggested.
You may also be interested in...
HIV "Salvage" Drug Efficacy May Be Shown With Half-Log Drop In Viral Load
A .5-log drop in viral load may be an optimal endpoint for testing "salvage" therapies in treatment-experienced HIV patients, FDA's Antiviral Drugs Advisory Committee concluded.
Time-To-Loss Of Virologic Response Acceptable Endpoint For HIV Drugs-FDA
Traditional approval of antiretroviral drugs may be based on clinical trials using a primary endpoint of time-to-loss of virologic response or on an endpoint of the proportion of patients whose HIV RNA levels fall below the acceptable assay level, a draft guidance released by FDA states.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011